Home

IONIS PHARMACEUTICALS INC

CIK 874015 · last filed 2020-10-14

IONIS PHARMACEUTICALS INC is a corporate insider who has filed 13 SEC Form 4 insider transactions across 2 companies since 2012. Across all open-market trades the lifetime net is +$222.5M, making them a net buyer over the disclosed history. The firm reports its address in Carlsbad, CA. 157 SEC filings were submitted jointly with C FRANK BENNETT.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

2

Total Filings

13

Lifetime Open-Market Net

$222.50M

Filer Profile

Reported Address
2855 GAZELLE COURT
CARLSBAD, CA 92010
Phone
(760) 931-9200
State of Incorporation
CA
Formerly Known As
ISIS PHARMACEUTICALS INC (1996–2015)
Related Filers
C FRANK BENNETT — 157 joint filings, latest 2026-07-09
B LYNNE PARSHALL — 155 joint filings, latest 2026-04-17
STANLEY T CROOKE — 137 joint filings, latest 2021-01-28
PATRICK R. O'NEIL — 137 joint filings, latest 2026-06-30
Brett P Monia — 130 joint filings, latest 2026-06-26
Richard S Geary — 115 joint filings, latest 2025-11-07
JOSEPH KLEIN III — 84 joint filings, latest 2026-07-06
ELIZABETH L HOUGEN — 82 joint filings, latest 2026-03-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AKCEA THERAPEUTICS, INC. (AKCA) Delisted 10%+ Owner 77,094,682 — — $225.00M 6 2019-12-19
Regulus Therapeutics Inc. (RGLS) Delisted Director 45,426 $8.16 $370.7K -$2.50M 6 2015-07-17

Recent Filings

13 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-10-14 — Buy (P) +21,237,715 $385.46M
2019-12-19 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Other (J) +6,873,344 $0 EDGAR
2019-04-02 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Other (J) +2,837,373 $0 EDGAR
2018-10-18 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Other (J) +1,671,849 $0 EDGAR
2018-08-06 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Other (J) +1,597,571 $0 EDGAR
2018-04-19 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Mixed +18,666,666 $200.00M EDGAR
2017-07-21 AKCEA THERAPEUTICS, INC. (AKCA) Delisted Mixed +45,447,879 $25.00M EDGAR
2015-07-17 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −343,133 -$3.64M EDGAR
2015-07-02 Regulus Therapeutics Inc. (RGLS) Delisted Mixed — -$143.0K EDGAR
2014-10-28 Regulus Therapeutics Inc. (RGLS) Delisted Sell (S) −113,084 -$1.59M EDGAR
Showing 1–10 of 13
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.